Experts issue new treatment algorithm for nasal polyps

Yardley-based Optinose, a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists, announced that the publication of a new stepped-care treatment algorithm in the International Forum of Allergy & Rhinology, “Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps,” recommends Exhalation Delivery System-fluticasone (EDS-FLU) for the treatment of patients with nasal polyps.
It also recommends EDS-FLU as a step in between initial care with standard intranasal steroids and before escalation of care with surgery or biologic medicines.
The algorithm was informed by evidence-based, peer-reviewed data supporting the use of therapeutic and interventional treatments to arrive at the recommended stepwise care paradigm. The growing number of medical and surgical treatment options available for patients with nasal polyps can cause confusion among providers regarding the optimal sequence for those treatment modalities. The algorithm seeks to lend order to treatment and serve as a basis for improving quality of care.

The publication discusses considerations in a pathway for care that incorporates several new treatments approved in recent years into a logical stepwise escalation of medical care, including but not limited to standard nasal steroid sprays, EDS-FLU, surgery, implants and biologics.
Optinose manufactures XHANCE, the only FDA-approved EDS to treat nasal polyps, which are soft, noncancerous growths high in the lining of the nasal passages or sinuses. Treatments for nasal polyps include, among others, standard topical intranasal steroid sprays, XHANCE, short bursts of oral steroids, surgery, implants and biologics.

---

Join our readers whose generous donations are making it possible for you to read our news coverage. Help keep local journalism alive and our community strong. Donate today.